VIROLOGICAL DETERMINANTS OF DRUG RESISTANCE IN CHRONIC HCV INFECTION
Grant number: 1066537 | Funding period: 2014 - 2016
New treatments for hepatitis C virus (HCV) infection are emerging. These drugs directly target key events in the viral life cycle. While these drugs are effective, the ability of HCV to mutate means that drug resistance can arise, leading to treatment failure. This is most likely in patients who do not respond to interferon-based therapy. This proposal will use new, highly sensitive sequencing approaches to identify the viral mutations and evolutionary pathways that lead to drug resistance.
Related publications (1)
Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia
T Papaluca, J O'Keefe, S Bowden, JS Doyle, M Stoove, M Hellard, AJ Thompson
BACKGROUND: Direct-acting antivirals (DAA) have revolutionised hepatitis C virus (HCV) treatment, and most regimens include an NS5..